Tumori Journal · 2003 · 14 citations · 5 references
MedicineGynecologyOncologyChemotherapyGynecologic OncologyMedical OncologyChemotherapy Toxicity ManagementMalignant NeoplasmsOvarian CancerToxicity ManagementChemotherapy-induced Ovarian ToxicityDrug Hypersensitivity ReactionsMalignant Ovarian NeoplasmsOvarian Cancer ChemotherapyOvarian Cancer TreatmentPlatinum HypersensitivityPlatinum-based Drug HypersensitivityPlatinum-based Regimens
Platinum-based therapy is considered the standard treatment for patients with advanced ovarian cancer. Carboplatin has a more favorable toxicity profile than cisplatin; however, hypersensitivity reactions to carboplatin have been reported occasionally. We reviewed 112 cases of ovarian cancer treated with carboplatin at our institute to identify the hypersensitivity reactions to this chemotherapeutic agent. Hypersensitivity reactions were documented in nine cases (8%). No deaths occurred, but the reactions were judged severe in three of the 112 patients (2.6%). In our own experience with patients showing idiosyncrasy to carboplatin we observed successful resolution after retreatment with cisplatin. Since patients who relapse after initial treatment with carboplatin often respond to it a second time, it is important to continue this treatment.
5
Clinical Features of Hypersensitivity Reactions to Carboplatin
Maurie Markman, Alexander Kennedy, Kenneth Webster et al. · Journal of Clinical Oncology · 1999 · 374 citations
Medicine, Oncology, Pharmacology +17